Bristol Myers Squibb stock: no new catalyst explains today’s move
BMY stock analysis and fair value · bull and bear case
The call: SageNoodle rates Bristol Myers Squibb Undervalued: base-case fair value USD 76 against a price of USD 59, 28% above the quote on a Long term horizon. No verified company announcement dated October 8 explains the day’s 0.2% rise; the attention count and nearby headlines do not establish a catalyst.
Bristol Myers Squibb stock is up 0.2% at $59.70, but no disclosed event in the latest filing explains the attention. The Q2 report shows growth and a valuation supported by cash generation, with pipeline durability still the test.
Valuation as of 8 Oct 2026 · Quote currency: USD. Latest quote: Fri, 09 Oct 2026 19:59:59 GMT.
Written with AI from the linked sources and reviewed by a SageNoodle editor. How we work.
Latest quote
USD 59.11
At publication
USD 59.70
Fair value
USD 75.60
Upside
+27.9%
P/E at publication
13.1x
EV/EBITDA
Not available
FCF yield
0.1%
ROIC 0.1% · Horizon Long term
Why Bristol Myers Squibb (BMY) stock is mispriced
- 01
No verified company announcement dated October 8 explains the day’s 0.2% rise; the attention count and nearby headlines do not establish a catalyst.
- 02
The latest filed quarter showed revenue rising to $12.973 billion from $12.269 billion year over year, while the six-month figure also rose; this supports near-term operating resilience, not proof that long-term replacement growth is secured.
- 03
At $59.70, the shares remain below the carried $75.60 fair value, supported by a 13.1x trailing P/E and 9.4% trailing FCF yield; elevated business and execution risk still warrants caution.
What Bristol Myers Squibb does and how it makes money
Bristol Myers Squibb (NYSE: BMY) is a Princeton-based pharmaceutical company that earns revenue by selling prescription medicines and through alliance and other revenue. Its Q2 FY2026 filing identifies product sales and alliance revenue, and reports results across a broad set of named medicines including Opdivo, Eliquis, Reblozyl and Camzyos. The latest report covers the three and six months ended June 30, 2026. Q2 FY2026 Form 10-Q
For the financial history and all coverage, see BRISTOL MYERS SQUIBB CO (BMY) company research.
Source documents
What happened to BMY stock today?
There is no verified company event in the available information that explains Bristol Myers Squibb’s small move on October 8, 2026. The stock is reported up 0.2% at $59.70, and the attention feed lists one fresh headline and one Reddit mention. Those counts describe attention, not its cause.
The latest company document is the Q2 FY2026 10-Q, filed July 30. Its reporting period ended June 30, so it is background on the business, not evidence of a fresh October 8 catalyst. A headline in the recent feed refers to a downgrade and pipeline doubt, but the headline alone cannot establish what the analyst argued or whether it explains today’s trading. Q2 FY2026 Form 10-Q
What changed in the latest reported results?
The latest quarterly filing reports Q2 FY2026 revenue of $12.973 billion, against $12.269 billion in the year-earlier quarter. Six-month revenue was $24.462 billion, versus $23.470 billion in the first half of FY2025, calculated by adding the filing’s net product sales and alliance and other revenue for each period. That is a genuine improvement in the reported top line, though one quarter cannot settle how durable it is. Q2 FY2026 Form 10-Q
Does this change the long-term thesis?
Not on the evidence available. Annual revenue was nearly flat in FY2025 at $48.19 billion, down 0.2% from FY2024. Operating margin was 19.4% and ROIC 11.6% in FY2025, while the current trailing figures show $11.4 billion of free cash flow. The combination is financially supportive: the company is generating cash and the share price is not demanding a high trailing earnings multiple. It does not by itself prove that newer products can offset pressure on established medicines over time.
Bristol Myers Squibb’s prior fair value of $75.60 remains the appropriate carried estimate because this day’s price action has no verified fundamental catalyst. At $59.70, that implies about 26.6% upside to fair value, calculated as ($75.60 / $59.70) - 1. The valuation is not a promise: a low multiple can reflect real concerns about growth durability and execution. The latest filing’s named portfolio and quarter are useful evidence, but do not alone resolve product-level trajectories.
What could prove the thesis wrong?
The central risk is that current cash generation and quarterly revenue growth fail to persist as the business transitions from older products to growth medicines. Net debt was $34.14 billion at Q2 FY2026, leaving less flexibility than the headline cash yield suggests. A reversal in revenue growth, weaker operating profitability or a sustained fall in free cash flow would undermine the value case; the next company results and product-specific disclosures can test that question.
For now, the most accurate answer to why BMY is moving today is that the cause is unclear. The latest reported quarter supports the existing thesis but does not justify changing its fair value or claiming that a new event has shifted the long-term outlook.
Follow SageNoodle on Google
Bristol Myers Squibb revenue, margins and cash flow
Revenue (USD, billions)
Margins (%)
Free cash flow (USD, billions)
Estimated ROIC (%)
Net debt (USD, billions)
Monetary values are in USD; revenue, FCF and net debt are in billions; EPS is per share. Missing values appear as gaps and “Not available.” Source: SEC EDGAR XBRL filings, latest restated values; quarterly cash flow derived from year-to-date figures; Q4 = fiscal year minus nine months. ROIC is NOPAT (21% tax) over debt plus equity.
| Period | Revenue | Gross % | Op % | FCF | EPS | ROIC % | Net debt |
|---|---|---|---|---|---|---|---|
| FY2016 | 19.4 | 74.5 | Not available | 1.84 | 2.65 | Not available | 1.48 |
| FY2017 | 20.8 | 70.7 | Not available | 4.22 | 0.61 | Not available | 1.55 |
| FY2018 | 22.6 | 71.3 | Not available | 6.12 | 3.01 | Not available | -0.02 |
| FY2019 | 26.1 | 69.1 | 19.0 | 7.37 | 2.01 | 4.02 | 33.8 |
| FY2020 | 42.5 | 72.3 | -16.2 | 13.3 | -3.99 | -6.16 | 35.8 |
| FY2021 | 46.4 | Not available | 17.5 | 15.2 | 3.12 | 7.97 | 30.4 |
| FY2022 | 46.2 | Not available | 16.7 | 11.9 | 2.95 | 8.70 | 29.8 |
| FY2023 | 45.0 | Not available | 18.8 | 12.7 | 3.86 | 9.67 | 28.1 |
| FY2024 | 48.3 | Not available | -17.4 | 13.9 | -4.41 | -10.1 | 39.1 |
| FY2025 | 48.2 | Not available | 19.4 | 12.8 | 3.46 | 11.6 | 34.6 |
What Bristol Myers Squibb management has said
Bristol Myers Squibb fair value: bear, base and bull scenarios
Dot marks the latest quote of USD 59.11.
Bear
25%USD 55
Illustrative direct equity valuation using an assumed normalized EPS multiple.
Equity value USD 112.35B ÷ 2.043B diluted shares
- Normalized EPS assumption
- $4.00 per share
- P/E assumption
- 13.75x
- Calculation
- $4.00 × 13.75 = $55.00 per share
Assumes earnings power contracts from the current trailing EPS base as product replacement and execution disappoint. This is a downside sensitivity, not a company forecast.
Base
50%USD 76
Carried prior coverage fair value; not recalibrated because no verified new event justifies a change.
Equity value USD 154.43B ÷ 2.043B diluted shares
- Fair value
- $75.60 per share, carried unchanged from prior coverage
- Equity value calculation
- $75.60 × 2.048 billion shares = $154.8288 billion
Retains the prior estimate. The current-day move lacks an evidenced fundamental catalyst; the latest results do not warrant replacing the existing base case.
Bull
25%USD 95
Illustrative direct equity valuation using an assumed normalized EPS multiple.
Equity value USD 194.06B ÷ 2.043B diluted shares
- Normalized EPS assumption
- $5.00 per share
- P/E assumption
- 19.0x
- Calculation
- $5.00 × 19.0 = $95.00 per share
Assumes stronger sustained earnings and a higher valuation multiple as investors gain confidence in growth and cash-flow durability. Neither input is company guidance.
Bristol Myers Squibb (BMY) stock: bullish vs bearish case
Bull case
- Trailing free cash flow of $11.4 billion and a 9.4% FCF yield support the valuation case if cash generation holds.
- The carried $75.60 fair value is substantially above the $59.70 share price.
Bear case
- FY2025 revenue declined slightly year over year, so recent quarterly growth has not yet established a sustained annual growth trend.
- The financial series shows $34.14 billion net debt at Q2 FY2026, which constrains flexibility.
- Pipeline and product-level durability remain unresolved in the evidence; disappointment could reduce earnings expectations and the multiple.
Bristol Myers Squibb stock risks
| Risk | Severity | Probability | Rationale |
|---|---|---|---|
| Product durability and replacement growth | High | Medium | |
| Leverage and cash-flow resilience | Medium | Medium | Net debt was $34.14 billion in Q2 FY2026. Lower cash generation would reduce balance-sheet flexibility. |
| Clinical and commercial execution | High | Medium | Pharmaceutical value depends on successful development and uptake; the source material does not establish outcomes for future pipeline assets. |
Bristol Myers Squibb catalysts: what could move BMY stock
- Next quarterly filing; date not suppliedNeutral
Next reported quarter
Watch revenue, operating profitability, cash generation and product-level disclosures for evidence that Q2 growth persists.
Bristol Myers Squibb fair value history
| Period | Fair value | Verdict | Note |
|---|---|---|---|
| Q2 FY2026 | USD 76 | Undervalued | No verified October 8 fundamental event warrants changing the carried fair value. |
Bristol Myers Squibb news
Bristol Myers Squibb Receives an FDA Approval, Adding a Potential Growth Asset
A Simply Wall St headline reported that Bristol Myers Squibb received an FDA approval. The supplied headline does not identify the product, indication, label, launch timing, or expected financial contribution.
Why this matters
Regulatory approval can extend the company’s marketed-product base and create incremental revenue and cash-flow potential, which is relevant as long-term valuation depends on replacing revenue exposed to product concentration and patent or exclusivity risk. The financial effect cannot be quantified from the supplied information, so the approval is a qualitative positive rather than a basis for changing fair value.
More on BRISTOL MYERS SQUIBB CO
Related reports
- Bristol Myers Squibb Raised Its Outlook as Gross Margin Fell
Earnings Update · 10 Sept 2026
Quarterly earnings
Bristol Myers Squibb stock: common questions
- Is Bristol Myers Squibb (BMY) stock undervalued or overvalued?
- SageNoodle rates Bristol Myers Squibb Undervalued: base-case fair value USD 76 against a price of USD 59, 28% above the quote on a Long term horizon. No verified company announcement dated October 8 explains the day’s 0.2% rise; the attention count and nearby headlines do not establish a catalyst.
- What is Bristol Myers Squibb's fair value?
- Bear USD 55 (25% probability, Illustrative direct equity valuation using an assumed normalized EPS multiple.); Base USD 76 (50% probability, Carried prior coverage fair value; not recalibrated because no verified new event justifies a change.); Bull USD 95 (25% probability, Illustrative direct equity valuation using an assumed normalized EPS multiple.). Retains the prior estimate. The current-day move lacks an evidenced fundamental catalyst; the latest results do not warrant replacing the existing base case.
- What is the bull case for BMY stock?
- Trailing free cash flow of $11.4 billion and a 9.4% FCF yield support the valuation case if cash generation holds. The carried $75.60 fair value is substantially above the $59.70 share price.
- What is the bear case for BMY stock?
- FY2025 revenue declined slightly year over year, so recent quarterly growth has not yet established a sustained annual growth trend. The financial series shows $34.14 billion net debt at Q2 FY2026, which constrains flexibility. Pipeline and product-level durability remain unresolved in the evidence; disappointment could reduce earnings expectations and the multiple.
- What are the biggest risks to Bristol Myers Squibb stock?
- Product durability and replacement growth (High severity): Leverage and cash-flow resilience (Medium severity): Net debt was $34.14 billion in Q2 FY2026. Lower cash generation would reduce balance-sheet flexibility. Clinical and commercial execution (High severity): Pharmaceutical value depends on successful development and uptake; the source material does not establish outcomes for future pipeline assets.
- What could move BMY stock next?
- Next quarterly filing; date not supplied: Next reported quarter. Watch revenue, operating profitability, cash generation and product-level disclosures for evidence that Q2 growth persists.
Company reference pages
Browse company filings and market quotes to check the latest information. These pages update over time and are separate from the documents cited in this report.